Literature DB >> 22074827

Role of ubiquitination in PCSK9-mediated low-density lipoprotein receptor degradation.

Yanqun Chen1, He Wang, Lan Yu, Xiaohong Yu, Yue-Wei Qian, Guoqing Cao, Jian Wang.   

Abstract

The proprotein convertases subtilisin kexin 9 (PCSK9) binds to the epidermal growth factor domain A (EGF-A) of low-density lipoprotein receptor (LDLR) and leads to its destruction. However, the intracellular processes leading to LDLR degradation have not been fully delineated. In this report, we show that PCSK9 treatment can lead to ubiquitination of LDLR, which was enhanced in the presence of proteasome inhibitor MG132. Furthermore, LDLR protein carrying mutations in the C-terminal ubiquitination sites was resistant to PCSK9-mediated degradation. Our data suggest that the ubiquitination system is involved in PCSK9-induced LDLR degradation.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22074827     DOI: 10.1016/j.bbrc.2011.10.110

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  4 in total

Review 1.  Potential of proprotein convertase subtilisin/kexin type 9 based therapeutics.

Authors:  Evan A Stein; Gary D Swergold
Journal:  Curr Atheroscler Rep       Date:  2013-03       Impact factor: 5.113

Review 2.  Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9).

Authors:  Rainer Schulz; Klaus-Dieter Schlüter; Ulrich Laufs
Journal:  Basic Res Cardiol       Date:  2015-01-20       Impact factor: 17.165

Review 3.  PCSK9 Variants in Familial Hypercholesterolemia: A Comprehensive Synopsis.

Authors:  Qianyun Guo; Xunxun Feng; Yujie Zhou
Journal:  Front Genet       Date:  2020-09-23       Impact factor: 4.599

4.  Inhibitory action of benzo[α]pyrene on hepatic lipoprotein receptors in vitro and on liver lipid homeostasis in mice.

Authors:  Hamed Layeghkhavidaki; Marie-Claire Lanhers; Samina Akbar; Lynn Gregory-Pauron; Thierry Oster; Nathalie Grova; Brice Appenzeller; Jordane Jasniewski; Cyril Feidt; Catherine Corbier; Frances T Yen
Journal:  PLoS One       Date:  2014-07-23       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.